The story of copyright's flagship drug presents a interesting case for investors in the drug sector. While initially a blockbuster success, producing billions, the patent lapse and the subsequent flood of cheaper versions have significantly impacted income. This poses questions about the ongoing sustainability of related therapeutic developments… Read More